New drug targets breast cancer brain tumors in early trial
NCT ID NCT05866432
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests a drug called datopotamab-deruxtecan in 20 people with triple-negative breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants must have newly diagnosed or growing brain metastases. The study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology
RECRUITINGVienna, State of Vienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.